Expanding the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study on uncommon peritoneal malignancies
Our findings suggest that CRS + HIPEC can be performed safely in highly selected patients with PM from uncommon primary tumors, achieving meaningful long-term survival in subsets such as breast and uterine cancers. Tumor biology, rather than clinical factors, emerged as the key determinant of survival. Given the rarity and heterogeneity of these malignancies, collaborative multicenter efforts and prospective registries are essential to establish standardized selection criteria and optimize outcomes.
Authors
- Daniela Di Pietrantonio (ORCID: https://orcid.org/0000-0002-1276-2382)
- Fabrizio D’Acapito (ORCID: https://orcid.org/0000-0001-6420-6209)
- Massimo Framarini
- Antonio Sommariva
- Paolo Sammartino
- Piero Vincenzo Lippolis
- Andrea Di Giorgio
Institutions
- University of Pisa (IT)
- Agostino Gemelli University Polyclinic (IT)
- Istituto Oncologico Veneto (IT)
- Ospedale G.B. Morgagni - L.Pierantoni (IT)
- Istituto Oncologico Romagnolo (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- World Journal of Clinical Oncology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.5306/wjco.v16.i12.112443
- Primary Topic
- Intraperitoneal and Appendiceal Malignancies
- Type
- article
- Field-Weighted Citation Impact
- 0.00